# RNASE6

## Overview
RNASE6 is a gene that encodes the protein ribonuclease A family member k6, a member of the ribonuclease A superfamily. This protein is categorized as an enzyme with significant roles in host defense mechanisms, particularly through its antimicrobial and antiviral activities. Ribonuclease A family member k6 is expressed in various human tissues, including the lung, heart, placenta, and kidneys, and is notably present in immune cells such as monocytes and neutrophils (Lee2019Functional; Narayanan2020Insights). The protein's structure is characterized by a kidney-shaped fold with a β-sheet core and α-helices, featuring a conserved catalytic triad essential for its enzymatic function (Narayanan2020Insights). RNASE6 is involved in the endonucleolytic cleavage of RNA and exhibits antimicrobial properties by destabilizing bacterial membranes and causing cell agglutination (Pulido2016Insights). Additionally, it has been shown to inhibit HIV replication by degrading viral RNA (Lee2019Functional). The gene's expression and activity are modulated in response to infections, highlighting its role in the innate immune response (Becknell2015Ribonucleases).

## Structure
RNase 6, a member of the ribonuclease A superfamily, exhibits a kidney-shaped fold typical of its family, with a β-sheet core flanked by α-helices (Narayanan2020Insights). The protein structure includes a conserved catalytic triad essential for its enzymatic activity, which is involved in the endonucleolytic cleavage of RNA (Narayanan2020Insights). The crystal structure of RNase 6 has been resolved in both its free and ligand-bound states, with the ligand-bound form showing specific interactions between the ligand and protein residues, although it lacks typical hydrogen bonding or electrostatic interactions seen in homologous RNases (Narayanan2020Insights).

RNase 6 also features a secondary active center, which contributes to its ribonucleolytic activity (Narayanan2020Insights). The N-terminal region of RNase 6 is particularly significant for its antimicrobial properties, characterized by a positive net charge and a high percentage of hydrophobic residues, facilitating interaction with bacterial membranes (Pulido2016Insights). Specific residues, such as Trp1 and Ile13, are crucial for its cell agglutination and antimicrobial activities (Pulido2016Insights). The protein's structural flexibility, especially in certain regions, is proposed to aid in its function, including bacterial membrane destabilization (Narayanan2020Insights).

## Function
RNASE6, also known as ribonuclease A family member k6, is a human enzyme involved in host defense mechanisms, particularly through its antimicrobial and antiviral activities. It is a member of the ribonuclease A superfamily and is expressed in various tissues, including the lung, heart, placenta, and kidneys, with significant expression in immune cells such as monocytes and neutrophils (Lee2019Functional; Narayanan2020Insights).

In healthy human cells, RNASE6 plays a crucial role in the innate immune response. It is primarily active in the extracellular space, where it exhibits antimicrobial activity against a range of bacterial pathogens, including both Gram-positive and Gram-negative bacteria. This activity is facilitated by its ability to destabilize bacterial membranes and cause agglutination, leading to membrane leakage and bacterial cell death (Pulido2016Insights). RNASE6 also demonstrates antiviral properties, notably inhibiting HIV replication by degrading viral RNA (Lee2019Functional).

The enzyme is upregulated in response to bacterial infections, particularly in the urinary tract, where it is expressed by myeloid cells such as monocytes and neutrophils. This suggests its role in the immune response to urinary tract infections (Becknell2015Ribonucleases). RNASE6's antimicrobial function is largely attributed to its cationic nature and specific structural features that facilitate interaction with bacterial surfaces (Pulido2016Insights).

## Clinical Significance
Mutations and alterations in the RNASE6 gene have been implicated in several diseases and conditions. A common single nucleotide polymorphism (SNP) in RNASE6, known as rs1045922, results in an amino acid substitution from arginine to glutamine at position 66 (R66Q). This polymorphism affects the protein's antimicrobial activity against uropathogenic Escherichia coli (UPEC), which is a major cause of urinary tract infections (UTIs). The R66 variant exhibits superior bactericidal activity compared to the Q66 variant, suggesting that individuals with the Q66 variant may have increased susceptibility to UTIs, particularly recurrent UTIs (Anguita2024A).

Alterations in RNASE6 expression have also been linked to atherosclerosis. In this condition, hypomethylation of the RNASE6 promoter leads to increased expression, which enhances the proliferation and migration of vascular smooth muscle cells, contributing to the progression of atherosclerosis (Fang2021Hypomethylation). Additionally, RNASE6 is identified as a key gene in diabetic nephropathy, where its expression correlates with immune and inflammatory responses, potentially serving as a biomarker for disease progression (Li2022Identification). These findings highlight the clinical significance of RNASE6 in various inflammatory and infectious diseases.

## Interactions
RNASE6, a member of the ribonuclease A superfamily, is involved in various interactions with nucleic acids and potentially other proteins. It exhibits binding interactions with ligands such as 5′-AMP and d(ACACA), which influence its structural and dynamical properties. The dissociation constant (K_d) for 5′-AMP binding is 154 ± 5 μM, while for d(ACACA), it is significantly lower at 8 ± 2 μM, indicating a stronger affinity for the latter. These interactions affect the conformational dynamics of RNASE6, particularly involving residues within and beyond the active site (Narayanan2020Insights).

RNASE6 also interacts with bacterial cell wall components, such as lipopolysaccharides (LPS), which is crucial for its antimicrobial activity. It binds to LPS on Gram-negative bacteria, facilitating membrane lysis and bacterial aggregation. Mutations at specific residues, such as Trp1 and Ile13, reduce its ability to bind LPS and diminish its antimicrobial efficacy (Pulido2016Insights). These interactions highlight RNASE6's role in host defense mechanisms, where it targets bacterial membranes and cell walls to exert its antimicrobial effects (Pulido2016Insights).


## References


[1. (Li2022Identification) Tongyi Li, Yanmei Wang, Chan Zhu, Yunjiao Yang, Cong Long, and Qiu Chen. Identification of ribonuclease 6 as an immunoinflammatory key gene associated with the glomerular injury in diabetic nephropathy. Scientific Reports, November 2022. URL: http://dx.doi.org/10.1038/s41598-022-24289-0, doi:10.1038/s41598-022-24289-0. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-022-24289-0)

[2. (Fang2021Hypomethylation) YongPeng Fang, JinShuang Li, XuDong Niu, NingShun Ma, and Jia Zhao. Hypomethylation of rnase6 promoter enhances proliferation and migration of murine aortic vascular smooth muscle cells and aggravates atherosclerosis in mice. Frontiers in Bioengineering and Biotechnology, July 2021. URL: http://dx.doi.org/10.3389/fbioe.2021.695461, doi:10.3389/fbioe.2021.695461. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fbioe.2021.695461)

[3. (Lee2019Functional) Heng-Huan Lee, Ying-Nai Wang, and Mien-Chie Hung. Functional roles of the human ribonuclease a superfamily in rna metabolism and membrane receptor biology. Molecular Aspects of Medicine, 70:106–116, December 2019. URL: http://dx.doi.org/10.1016/j.mam.2019.03.003, doi:10.1016/j.mam.2019.03.003. This article has 20 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2019.03.003)

[4. (Pulido2016Insights) David Pulido, Javier Arranz-Trullén, Guillem Prats-Ejarque, Diego Velázquez, Marc Torrent, Mohammed Moussaoui, and Ester Boix. Insights into the antimicrobial mechanism of action of human rnase6: structural determinants for bacterial cell agglutination and membrane permeation. International Journal of Molecular Sciences, 17(4):552, April 2016. URL: http://dx.doi.org/10.3390/ijms17040552, doi:10.3390/ijms17040552. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms17040552)

[5. (Anguita2024A) Raul Anguita, Guillem Prats-Ejarque, Mohammed Moussaoui, Brian Becknell, and Ester Boix. A common polymorphism in rnase6 impacts its antimicrobial activity toward uropathogenic escherichia coli. International Journal of Molecular Sciences, 25(1):604, January 2024. URL: http://dx.doi.org/10.3390/ijms25010604, doi:10.3390/ijms25010604. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25010604)

[6. (Becknell2015Ribonucleases) Brian Becknell, Tad E. Eichler, Susana Beceiro, Birong Li, Robert S. Easterling, Ashley R. Carpenter, Cindy L. James, Kirk M. McHugh, David S. Hains, Santiago Partida-Sanchez, and John D. Spencer. Ribonucleases 6 and 7 have antimicrobial function in the human and murine urinary tract. Kidney International, 87(1):151–161, January 2015. URL: http://dx.doi.org/10.1038/ki.2014.268, doi:10.1038/ki.2014.268. This article has 63 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ki.2014.268)

[7. (Narayanan2020Insights) Chitra Narayanan, David N. Bernard, Myriam Létourneau, Jacinthe Gagnon, Donald Gagné, Khushboo Bafna, Charles Calmettes, Jean-François Couture, Pratul K. Agarwal, and Nicolas Doucet. Insights into structural and dynamical changes experienced by human rnase 6 upon ligand binding. Biochemistry, 59(6):755–765, January 2020. URL: http://dx.doi.org/10.1021/acs.biochem.9b00888, doi:10.1021/acs.biochem.9b00888. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/acs.biochem.9b00888)